Hepatitis B virus (HBV) reactivation after chemotherapy or immunosuppressive therapy is a cause of liver-related morbidity and mortality. Not all chronic hepatitis B patients will lead to HBV reactivation. The incidence is 0.3%-30.2% according to the reports. The mechanism of HBV reactivation is still unclear, but it is believed that the viral load is increasing due to the suppression of immune response. No uniform diagnostic criteria are available. HBV reactivation can be confirmed by an increase of serum HBV DNA level. Recently, awareness of reactivation of occult HBV has been improved, especially in HBV endemic area. Preemptive antiviral therapy was the best approach to prevent the HBV reactivation. HBV reactivation can lead to acute hepatitis, severe hepatitis and acute liver failure. Therefore, it is worthy of great attention and further study. Antiviral therapy is safe and effective to prevent HBV reactivation. genotype B. They suggested that males and those with HBV DNA ≥ 1000 IU/ml need to be followed up. Under circumstances of tumor, autoimmune diseases, malignant blood disease, rheumatism and other diseases, the immune inhibitor or chemotherapy is the most effective treatment method. However, the patients with negative original HBV infection, i.e. HBsAg-negative and antibodies to hepatitis B core antigen (anti-HBc) positive patients can develop HBV reactivation even 2 years after stopping immunosuppression. 1, 5 ,6 I n t h e p r o c e s s o f i m m u n e t h e r a p y o r chemotherapy, immune function is suppressed, which results in HBV replication in vivo and infecting more liver cells. HBV DNA has response element of glucocorticoid. Glucocorticoid can activate HBV gene expression and induce HBV replication. Rituximab may lead to mature B cells and plasma cells decreasing, resulting in antibody production decline, causing humoral immune dysfunction, thus inducing HBV reactivation. 2, 7, 8 Liver injury induced by HBV reactivation can occur after stopping drug or in the process of medication. Because a great quantity replication of HBV in liver cells, and attack from cytotoxic
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BV reactivation refers to the previous history of HBV infection has been deactivated or recovered under some circumstances, such as chemotherapy, immunosuppression therapy, liver resection under the condition of serum HBV DNA is increasing, always accompanied by hepatitis flare. Elevated transaminase levels and clinical manifestations of acute hepatitis may cause acute liver failure, and even death. HBV reactivation usually uses HBV DNA level as diagnostic criteria, namely HBV DNA > 10 3 IU/ ml, or 2 consecutive detection of hepatitis B surface antigen (HBsAg) positive caused by chemotherapy, immunosuppression therapy, operation and other factors [1] [2] [3] in patients with undetectable HBV DNA or HBsAg. Generally, the inactivation rate of HBV after the HBV reactivation is quite low. Tohme et al 4 followed up 414 patients in the inactive phase of hepatitis B (HBV DNA < 2000 IU/ml, and normal alanine aminotransferase for 12 months) for 10 years. A total of 36 (9%) persons had reactivation with an annual incidence of 1.2%. Risk factors for HBV reactivation were male with HBV DNA ≥ 1000 IU/ml, and HBV genotype B. They suggested that males and those with HBV DNA ≥ 1000 IU/ml need to be followed up. Under circumstances of tumor, autoimmune diseases, malignant blood disease, rheumatism and other diseases, the immune inhibitor or chemotherapy is the most effective treatment method. However, the patients with negative original HBV infection, i.e. HBsAg-negative and antibodies to hepatitis B core antigen (anti-HBc) positive patients can develop HBV reactivation even 2 years after stopping immunosuppression. 1, 5 ,6 I n t h e p r o c e s s o f i m m u n e t h e r a p y o r chemotherapy, immune function is suppressed, which results in HBV replication in vivo and infecting more liver cells. HBV DNA has response element of glucocorticoid. Glucocorticoid can activate HBV gene expression and induce HBV replication. Rituximab may lead to mature B cells and plasma cells decreasing, resulting in antibody production decline, causing humoral immune dysfunction, thus inducing HBV reactivation. 2, 7, 8 Liver injury induced by HBV reactivation can occur after stopping drug or in the process of medication. Because a great quantity replication of HBV in liver cells, and attack from cytotoxic DOI: 10.1515/ii-2017-0095 for anti-HBc are at risk of HBV reactivation under immunosuppressive conditions. Inuzuka et al 12 examined the prevalence of the G1896A variant in 14 individuals originally HBsAg-negative but antiHBc-positive that experienced HBV reactivation and 44 healthy individuals that were HBsAg-negative but anti-HBc-positive without HBV reactivation, and found that the G1896A variant was detected in 42.9% (6/14) of cases, including two cases with fatal liver failure, while it was observed in the liver tissue of 11.4% (5/44) of indivividuals with OBI. They thought that reactivation from OBI was characterized by low genetic heterogeneity, with the wild-type G1896 or G1896A variant prevalent.
In a word, OBI may be involved in different clinical contexts, including the transmission of the infection by blood transfusion, liver transplantation and its acute reactivation when an immunosuppressive status occurs. Moreover, much evidence suggests that it may contribute to the development of cirrhosis and have an important role in hepatocarcinogenesis. 
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immunosuppression and HBV reactivation Immunosuppressive drugs associated with HBV reactivation contain corticosteroids primarily (dexamethasone, prednisone, prednisolone) and T cells to liver cells infected by HBV, can cause inflammation, necrosis and apoptosis, eventually lead to fibrosis.
Occult HBV infection and HBV reactivation
Occult HBV infection (OBI) is defined as presence of HBV DNA in the liver tissue of patients with serologically undetectable HBsAg. Majority of OBI are positive for anti-HBs and/or anti-HBc and minor portion are negative for all HBV markers. The study found that HBV persists in the presence of covalently closed circular DNA (cccDNA). OBI increases the risk of HBV transmission through transfusion, hemodialysis and organ transplantation. Therefore, in order to patient's safety, the OBI should be determined and effectively screened. Antiviral therapy is needed in HBsAg-negative transplant. Patients who are anti-HBc positive can prevent the recurrence of HBV infection through it. Since HBV replication can be suppressed by immune surveillance system in OBI patients. Immunosuppression results in massive HBV replication. This leads to acute hepatitis and sometimes mortality when immune surveillance is recovered after stopping immunosuppressive drugs/ anticancer chemotherapy. 9, 10 Occult HBV infection may occur in subject with solid tumours, although the risk of its reactivation under chemotherapy appears to be very low. 10 Chen et al 11 retrospectively analyzed 322 occult HBV carriers who received kidney transplantation, and found 15 cases (4.7%) had HBV reactivation. Older age and anti-T-cell antibodies may increase the risk of HBV reactivation, whereas lamivudine prophylaxis may prevent HBV reactivation after kidney transplantation. OBI may have impacted on several different clinical contexts. In fact, it can be transmitted through blood transfusion and liver transplantation causing classic forms of hepatitis B in newly infected individuals. The process of an immunotherapy or chemotherapy may induce OBI reactivation and develop to acute and severe hepatitis. OBI can favor the progression of liver fibrosis. The possible evidence suggests that the effect of OBI to the establishment of cirrhosis also implies its possible indirect role in the development of hepatocellular carcinoma. 10 Individuals negative for HBsAg but positive monoclonal antibodies (rituximab, tocilizumab, etanercept) .
With the increasing use of immunosuppressive therapy, HBV reactivation in endemic regions becomes a clinical problem requiring special attention. A recent survey clarified that HBV reactivation related to immunosuppressive therapy had been increasing in patients with malignant lymphoma, other hematological malignancies, oncological or rheumatoid diseases. Rituximab plus steroid-containing chemotherapy was identified as a risk factor for HBV reactivation in HBsAg negative patients with malignant lymphoma. 16 The use of tumor necrosis factor-α (TNF-α) inhibitors is increasing especially in patients with rheumatoid arthritis (RA).
As TNF-α inhibitors are strongly immunosuppressive, the occurrence of HBV reactivation has been recently observed. Reports suggest a higher risk of complicating HBV reactivation in carriers who are treated with TNF-α inhibitors. Therefore, HBV carriers are recommended to undergo prophylactic administration of nucleotide analogs (NAs). Tanaka et al 17 uncovered several characteristics of the de novo hepatitis B due to TNF-α inhibitors. First, the time between the start of TNF-α inhibitors and the occurrence of de novo hepatitis was longer than one year. Second, patients were usually treated with additional non-biologic agents, which also had immunosuppressive effects. Third, the disease could be fatal. Fourth, several types of TNF-α inhibitors exhibited a risk of developing de novo hepatitis. The incidence of de novo hepatitis B is 0-5%/year. HBV reactivation rate of patients with rheumatic disease receiving prednisone is 20.8% compared to only 4.46% and 9.52% of patients treated with DMARDs (disease-modifying anti-rheumatic drugs) or TNFBA (TNF-α-blocking agents), respectively. This long-term (16-48 months) follow-up suggests that pre-emptive antiviral therapy should be administered in patients receiving prednisone therapy for rheumatic disease. 
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A total of 109 patients with malignant lymphoma or multiple myeloma are in one study. They were checked anti-HBs or anti-HBc before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti-HBs and 59 (54.1%) had anti-HBc. Among the 59 anti-HBc positive patients, 6.8% (4/59) showed HBV reactivation. 2 The rate of HBV reactivation is low in patients who were HBsAg negative/antiHBc positive receiving rituximab-based combination chemotherapy without concomitant antiviral prophylaxis. But in the elderly patients, particularly those without anti-HBs seemed particularly at risk. Juvenile rheumatoid arthritis is a common chronic inflammatory disease. Some of the drugs used for the treatment have immunosuppressive activity. One of the serious side-effects of immunosuppressive treatment is activation of opportunistic pathogens. HBV is one of these pathogens. HBV reactivation can cause liver damage and death, so antiviral therapy is recommended. 26 were HBsAg-negative/HBcAb-positive before HSCT. Overall survival, non relapse mortality (NRM), acute and chronic graft vs. host disease were similar in HBcAb-positive and HBcAb-negative patients. Reactivation occurred in 14 patients (10%) within a median of 19 months after HSCT (range 9-77). Cause-specific hazard for reactivation was increased in patients who received rituximab treatment. No differences in overall survival and NRM were found between patients with and without HBV reactivation. The donor 's immunity was independently and consistently associated with a decreased risk of HBV reactivation.
R h e u m a t o i d a r t h r i t i s t h e r a p y a n d H B V reactivation
Prophylaxis with lamivudine is recommended for HBcAb-positive allogenic hematopoietic stem cell transplant (HSCT) recipient, but the optimal timing for the institution and duration of the prophylaxis is still unknown. In addition, considering the high rate of mortality associated with HBV reactivation, the most potent and long-term effective antiviral regimen should be considered. Milazzo et al 22 reported a case of late onset of HBV reactivation after a longterm prophylaxis with prophylaxis with lamivudine in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.
Radio frequency ablation or hepatic resection and HBV reactivation
Radio frequency ablation (RFA) is a local ablation therapy for hepatocellular carcinoma in the application of the most extensive ablation technique. The incidence of HBV reactivation was lower in patients who received liver resection to treat HBV-related hepatocellular carcinoma. Antiviral therapy prior to the hepatic resection treatment may be beneficial for reducing the incidence of HBV reactivation. A study found that the incidence was significantly lower in the RFA group than in the liver resection group (5.6% vs. 14.0%, P = 0.034). The univariate and multivariate analysis indicated that the treatment type were significant risk factors of HBV reactivation. However, the incidence of HBV reactivation in patients who did not receive antiviral therapy was higher than in those Tamori et al 27 enrolled 50 patients with RA who had anti-HBc and who had started treatment with DMARDs, including who had received anti-TNFα. HBV reactivation occurred in 2 of 5 patients with HBsAg and in 1 of 45 patients without HBsAg. The inciedence of HBV reactivation was low in RA. Prophylactic therapy with entecavir were effective to prevent HBV-associated liver failure in patients with HBsAg.
Liver transplantation in tumor patients with HBV reactivation Acute on chronic liver failure (ACLF) occurs in tumor patients because of HBV reactivation. Kim et al 28 studied twenty patients who underwent orthotopic liver transplantation (OLT) for ACLF due to HBV reactivation. Study revealed that OLT is a feasible and effective approach in ACLF due to HBV reactivation in select lymphoma patients.
Prevention of HBV reactivation
At present, whether the HBsAg (-), HBcAb (+) need prophylactic antiviral therapy is still controversial. "China Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010)" clearly pointed out that the HBsAg (-) and HBcAb (+) patients who acceptted long-term or high-dose immunosuppressive or cytotoxic drugs should be closely monitored the HBV DNA and HBsAg. If positive, it should be combined with antiviral drug. For patients with baseline HBV DNA < 2 000 IU/ ml, it should continue therapy for 6 months after completing chemotherapy or immunosuppressive therapy. First, such patients especially occult HBV infection patients should be routinely performed HBV monitorings. HBV DNA and liver function should be closely monitored during treatment. In summary, HBV associated with hepatocellular carcinoma, B cell lymphoma underwent with monoclonal antibody chemotherapy, radiotherapy, o p e r a t i o n , r h e u m a t o i d a r t h r i t i s r e c e i v i n g immunosuppressive therapy, allogeneic hematopoietic stem cell transplantation and liver transplantation should be closely monitored HBsAg. HBV DNA can early detect HBV reactivation. In order to prevent HBV reactivation, consensus has been forged that antiviral treatment is an effective and safe approach. 
